The Reported Adverse Effects Related to Biological Agents Used for the Treatment of Rheumatic Diseases in Turkey

KILIÇ, Erkan; ÖZGÖÇMEN, Salih; AKGÖL, Gürkan; KILIÇ, GAMZE; Akgul, Ozgur

The Reported Adverse Effects Related to Biological Agents Used for the Treatment of Rheumatic Diseases in Turkey

Erkan KILIÇ, (Erciyes Üniversitesi, Tıp Fakültesi, Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı, Romatoloji Bilim Dalı, Kayseri, Türkiye)

Gamze KILIÇ, (Erciyes Üniversitesi, Tıp Fakültesi, Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı, Romatoloji Bilim Dalı, Kayseri, Türkiye)

Özgür AKGÜL, (Erciyes Üniversitesi, Tıp Fakültesi, Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı, Romatoloji Bilim Dalı, Kayseri, Türkiye)

Gürkan AKGÖL, (Bingöl Devlet Hastanesi, Fiziksel Tıp ve Rehabilitasyon Kliniği, Bingöl, Türkiye)

Salih ÖZGÖÇMEN (Erciyes Üniversitesi, Tıp Fakültesi, Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı, Romatoloji Bilim Dalı, Kayseri, Türkiye)

Turkish Journal of Rheumatology(.)Archives of Rheumatology

4 0

Yıl: 2013 Cilt: 28 Sayı: 3 Sayfa Aralığı: 149 - 162 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

The Reported Adverse Effects Related to Biological Agents Used for the Treatment of Rheumatic Diseases in Turkey

Öz:

Amaç: Bu çalışmada Türkiye'de romatizmal hastalıkların tedavisinde kullanılan biyolojik ajanlara bağlı gelişen bildirilmiş yan etkiler derlendi.Hastalar ve yöntemler: Ocak 2000 ile Ocak 2012 tarihleri arasında romatizmal hastalıkların tedavisinde kullanılan infliksimab, etanersept, adalimumab, anakinra, rituksimab dahil olmak üzere biyolojik ajanlara bağlı gelişen yan etkileri bildiren olgu ve olgu serileri MedLine, Web of Science ve Scopus veri tabanları kullanılarak İngilizce ve Türkçe dillerinde tarandı.Bulgular: Literatürde Türkiye'den biyolojik ajana bağlı yan etki görülen romatizmal hastalıklı toplam 53 olgu (21 erkek, 32 kadın) bildirilmiştir. Yaş ortalaması 39.0±15.6 yıl ve ortalama hastalık süresi 10.6±8.2 yıl idi. Biyolojik ajanlara başlanması ile yan etkinin ortaya çıkması arasındaki geçen süre ortalama 8.8±9.2 aydı. Biyolojik ajan kullanımına bağlı olarak en sık görülen yan etki ankilozan spondilit (AS) ve romatoid artrit (RA) hastalarında gözlendi. En sık bildirilen yan etki 14 hastada (%26.4) tüberküloz idi. Diğer yan etkiler psöriyazis (%15.1), solid tümör (%7.6), lenfoma (%5.7), ilaca bağlı lupus (%3.8) ve menstrüel kanama (%3.8) idi. Yan etki gelişen olguların toplam %77.4'ünde biyolojik tedaviler sonlandırıldı.Sonuç: Biyolojik ajanlar nispeten güvenli olmakla beraber, nadiren ciddi yan etkilere neden olabilir. Türkiye'de tüberküloz orta derecede endemik bir hastalık olması nedeniyle, biyolojik ajan tedavisi (özellikle anti-TNF ve abatasept) planlanan hastalar tedavi öncesinde ve tedaviye başladıktan sonra tedavinin olası riskleri açısından bilgilendirilmeli ve yakından takip edilmelidir

Anahtar Kelime:

Konular: Romatoloji

Romatizmal Hastalıkların Tedavisinde Biyolojik Ajanların Kullanımına Bağlı Türkiye'de Bildirilmiş Yan Etkiler

Öz:

Objectives: This study aims to review the reported adverse events related to the use of biological agents used for the treatment of rheumatic diseases in Turkey. Patients and methods: Between January 2000 and January 2012, the literature was searched in English and Turkish for case reports and case series using the MedLine, Web of Science, and Scopus databases reporting adverse effects related to the use of biological agents including infliximab, etanercept, adalimumab, anakinra, rituximab which were used for the treatment of rheumatic diseases. Results: A total of 53 patients (21 males, 32 females) with rheumatic disease who suffered from adverse effects related to the use of biological agents were reported in Turkey in the literature. The mean age was 39.0±15.6 years, while the mean disease duration was 10.6±8.2 years. The mean time from the initiation of the biological agents to the onset of the adverse events was 8.8±9.2 months. The most frequently seen biological agent- related adverse effects were observed in patients with ankylosing spondylitis (AS) and rheumatoid arthritis (RA). Tuberculosis (TB) was the most commonly reported adverse effect with in 14 patients (26.4%). Other adverse events included psoriasis (15.1%), solid tumors (7.6%), lymphoma (5.7%), drug-induced lupus (3.8%), and menstrual bleeding (3.8%). A total of 77.4% patients who suffered from adverse events discontinued biological therapies. Conclusion: Biologic agents are relatively safe; however, they may rarely lead to serious adverse events. As tuberculosis is a moderate endemic disease in Turkey, patients who are scheduled for biological agents (anti-TNF and abatacept particularly) should be informed about the potential risks of biological therapy and monitored closely before and after the initiation of treatment

Anahtar Kelime:

Konular: Romatoloji

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

Bachmann F, Nast A, Sterry W, Philipp S. Safety and efficacy of the tumor necrosis factor antagonists.Semin Cutan Med Surg 2010;29:35-47.
Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis 2012;71 Suppl 2:i2-45.
Antoni C, Braun J. Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol 2002;20:S152-7.
Cush JJ. Unusual toxicities with TNF inhibition: heart failure and drug-induced lupus. Clin Exp Rheumatol 2004;22:S141-7.
Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-7.
Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004;50:372-9.
Kisich KO, Higgins M, Diamond G, Heifets L. Tumor necrosis factor alpha stimulates killing of Mycobacterium tuberculosis by human neutrophils. Infect Immun 2002;70:4591-9.
Kaneko H, Yamada H, Mizuno S, Udagawa T, Kazumi Y, Sekikawa K, et al. Role of tumor necrosis factor- alpha in Mycobacterium-induced granuloma formation in tumor necrosis factor-alpha-deficient mice. Lab Invest 1999;79:379-86.
Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat 2004;15:280-94.
Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Röwert J, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 2007;156:486-91.
McCain ME, Quinet RJ, Davis WE. Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology (Oxford) 2002;41:116-7.
Bleumink GS, ter Borg EJ, Ramselaar CG, Stricker BH. Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford) 2001;40:1317-9.
Soliotis F, Glover M, Jawad AS. Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis. Ann Rheum Dis 2002;61:850-1.
Gilaberte Y, Coscojuela C, Vázquez C, Roselló R, Vera J. Perforating folliculitis associated with tumour necrosis factor-alpha inhibitors administered for rheumatoid arthritis. Br J Dermatol 2007;156:368-71.
Gerster JC, Dudler J. Cellulitis caused by Capnocytophaga cynodegmi associated with etanercept treatment in a patient with rheumatoid arthritis. Clin Rheumatol 2004;23:570-1.
Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011;CD008794.
Inanc N, Direskeneli H. Serious infections under treatment with TNF-alpha antagonists compared to traditional DMARDs in patients with rheumatoid arthritis. Rheumatol Int 2006;27:67-71.
Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009;68:1136-45.
Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403-12.
Díaz-Lagares C, Pérez-Alvarez R, García-Hernández FJ, Ayala-Gutiérrez MM, Callejas JL, Martínez-Berriotxoa A, et al. Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. Arthritis Res Ther 2011;13:R112.
Geirsson AJ, Statkevicius S, Víkingsson A. Septic arthritis in Iceland 1990-2002: increasing incidence due to iatrogenic infections. Ann Rheum Dis 2008;67:638-43.
Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Ustianowski AP, Helbert M, et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011;70:1810-4.
Korkmaz C, Kaşifoğlu T. Development of recurrent pseudoseptic arthritis in a patient with rheumatoid arthritis receiving TNF-alpha blocker. Joint Bone Spine 2006;73:767-8.
Keystone EC. Safety of biologic therapies--an update. J Rheumatol Suppl 2005;74:8-12.
Sari I, Birlik M, Akar S, Onen F, Kargi A, Akkoc N. Atypical infectious mononucleosis in a patient receiving tumor necrosis factor alpha inhibitory treatment. Rheumatol Int 2009;29:825-6.
Akgul O, Ozgocmen S. Infliximab and brucellosis: not the usual suspects, this time. Mod Rheumatol 2011;21:313-5.
Sari I, Birlik M, Gonen C, Akar S, Gurel D, Onen F, et al. Cytomegalovirus colitis in a patient with Behcet's disease receiving tumor necrosis factor alpha inhibitory treatment. World J Gastroenterol 2008;14:2912-4.
Kalyoncu U, Karadag O, Akdogan A, Kisacik B, Erman M, Erguven S, et al. Pneumocystis carinii pneumonia in a rheumatoid arthritis patient treated with adalimumab. Scand J Infect Dis 2007;39:475-8.
Long R, Gardam M. Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection. CMAJ 2003;168:1153-6.
Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis
Baronnet L, Barnetche T, Kahn V, Lacoin C, Richez C, Schaeverbeke T. Incidence of tuberculosis in patients with rheumatoid arthritis. A systematic literature review. Joint Bone Spine 2011;78:279-84.
Sester U, Junker H, Hodapp T, Schütz A, Thiele B, Meyerhans A, et al. Improved efficiency in detecting cellular immunity towards M. tuberculosis in patients receiving immunosuppressive drug therapy. Nephrol Dial Transplant 2006;21:3258-68.
Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010;69:522-8.
Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, et al. Risk of tuberculosis is higher with anti- tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009;60:1884-94.
Türkiye'de verem savaşı 2010 raporu. Başak Matbaacılık ve Tan. Hiz. Ltd. Şti, 2010. (Accessed 25.12.12, 2012. Available from: http://www.ehsm.gov.tr/Sub/verem_ savas_dispanseri/files/dokumanlar/turkiyede_verem_ savasi_2010_raporu.pdf.
Elbek O, Uyar M, Aydin N, Börekçi S, Bayram N, Bayram H, et al. Increased risk of tuberculosis in patients treated with antitumor necrosis factor alpha. Clin Rheumatol 2009;28:421-6.
British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005;60:800-5.
Williams GM. Antitumor necrosis factor-alpha therapy and potential cancer inhibition. Eur J Cancer Prev 2008;17:169-77.
Nair B, Raval G, Mehta P. TNF-alpha inhibitor etanercept and hematologic malignancies: report of a case and review of the literature. Am J Hematol 2007;82:1022-4.
Pay S; Society for Research and Education in Rheumatology of Turkey. Risk of cancer in Turkish patients after treatment with TNF antagonists. Rheumatology (Oxford) 2008;47:548-9.
Geborek P, Bladström A, Turesson C, Gulfe A, Petersson IF, Saxne T, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005;64:699-703.
Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1414-20.
Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005;32:2130-5.
Baecklund E, Ekbom A, Sparén P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998;317:180-1.
Mercer LK, Green AC, Galloway JB, Davies R, Lunt M, Dixon WG, et al. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2012;71:869-74.
Solomon DH, Mercer E, Kavanaugh A. Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results. Arthritis Rheum 2012;64:21-32.
Cansu DU, Kasifoglu T, Açkaln M, Korkmaz C. The development of primary cutaneous adenoid cystic carcinoma in a patient with ankylosing spondylitis treated with etanercept. South Med J 2009;102:738-40.
Simsek I, Pay S, Dinc A, Erdem H, Kurt B. Atypical carcinoid tumor of the thymus with ectopic ACTH production developed during the course of etanercept treatment--case report. Clin Rheumatol 2007;26:1561-2.
Erten S. Endometrium cancer in a female with psoriatic arthritis treated with TNF alpha antagonist adalimumab. Rheumatol Int 2011;31:1537-8.
Pamuk ON, Harmandar F. A case of cervical spine meningioma following etanercept use in a patient with RA. Nat Rev Rheumatol 2009;5:457-60.
Aksu K, Donmez A, Ertan Y, Keser G, Inal V, Oder G, et al. Hodgkin's lymphoma following treatment with etanercept in ankylosing spondylitis. Rheumatol Int 2007;28:185-7.
Aksu K, Cagirgan S, Ozsan N, Keser G, Sahin F. Non- Hodgkin's lymphoma following treatment with etanercept in ankylosing spondylitis. Rheumatol Int 2011;31:1645-7.
Sanli H, Ataman S, Akay BN, Yilmaz A, Yildizlar D, Gürgey E. Mycosis fungoides in a patient with ankylosing spondylitis during infliximab therapy. J Drugs Dermatol 2007;6:834-6.
Kerbleski JF, Gottlieb AB. Dermatological complications and safety of anti-TNF treatments. Gut 2009;58:1033-9.
Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005;7:R666-76.
Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat 2009;20:100-8.
Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis
Wetter DA, Davis MD. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc 2009;84:979-84.
Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 2008;37:381-7.
Katz U, Zandman-Goddard G. Drug-induced lupus: an update. Autoimmun Rev 2010;10:46-50.
Bodur H, Eser F, Konca S, Arikan S. Infliximab-induced lupus-like syndrome in a patient with ankylosing spondylitis. Rheumatol Int 2009;29:451-4.
Altindag O, Aydeniz A, Gursoy S, Yagiz E, Koca I. Lupus- like syndrome during anti TNF-alpha therapy: a case report. Romatizma 2008;23:154-6.
Lelong J, Duburque C, Fournier C, Colombel JF, Desreumaux P, Tonnel AB, et al. Desensitisation to infliximab in patients with Crohn's disease. Rev Mal Respir 2005;22:239-46.
Bavbek S, Aydın O, Ataman S, Cahill K, Castells M. Injection-site reaction to etanercept: role of skin test in the diagnosis of such reaction and successful desensitization. Allergy 2011;66:1256-7.
Abadoglu O, Epozturk K, Atayik E, Kaptanoglu E. Successful rapid rituximab desensitization for hypersensitivity reactions to monoclonal antibodies in a patient with rheumatoid arthritis: a remarkable option. J Investig Allergol Clin Immunol 2011;21:319-21.
Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. Demyelination occurring during anti- tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9.
Cruz Fernández-Espartero M, Pérez-Zafrilla B, Naranjo A, Esteban C, Ortiz AM, Gómez-Reino JJ, et al. Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. Semin Arthritis Rheum 2011;41:524-33.
Cay HF, Gungor HA, Sezer I, Kacar C, Balci N. Adverse effect of TNF-alpha blocker? Demyelination in an ankylosing spondylitis patient: a case report. J Clin Pharm Ther 2006;31:645-8.
Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo- controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096-103.
Lunt M, Watson KD, Dixon WG; British Society for Rheumatology Biologics Register Control Centre Consortium, Symmons DP, Hyrich KL; British Society for Rheumatology Biologics Register. No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2010;62:3145-53.
Altindag O, Aydeniz A, Gursoy S. A Case with Anti TNF- ? Induced Bullous Pemhigoid. Turk J Rheumatol 2010;25:214-6.
Deniz D, Ebru U, Ajda B, Gulsum TM, Semih T, Aytul C. A case of cellulitis causing tissue defect during etanercept therapy. Rheumatol Int 2012;32:241-4.
Dagci H, Zeyrek F, Gerzile YK, Sahin SB, Yagci S, Uner A. A case of myiasis in a patient with psoriasis from Turkey. Parasitol Int 2008;57:239-41.
Sendur OF, Turan Y, Berkit IK, Tastaban E. Angio- oedema in a patient treated with etanercept for rheumatoid arthritis. Basic Clin Pharmacol Toxicol 2009;104:488-90.
Sari I, Akar S, Birlik M, Sis B, Onen F, Akkoc N. Anti-tumor necrosis factor-alpha-induced psoriasis. J Rheumatol 2006;33:1411-4.
Tutar E, Ekici F, Naçar N, Arici S, Atalay S. Delayed maculopapular, urticarial rash due to infliximab in two children with systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford) 2004;43:674-5.
Yazisiz V, Avci AB, Erbasan F, Yildirim B, Terzioğlu E. Development of Crohn's disease following anti-tumour necrosis factor therapy (etanercept). Colorectal Dis 2008;10:953-4.
Ekici B, Aydın K, Cantez S, Ergül Y, Tatlı B. Etanercept- induced encephalopathy in a 7-year-old child. Pediatr Neurol 2011;45:271-3.
Bodur H, Eser F, Konca S, Arikan S. Infliximab-induced lupus-like syndrome in a patient with ankylosing spondylitis. Rheumatol Int 2009;29:451-4.
Capkin E, Karkucak M, Yayli S, Aydin Çapkin A, Tosun M. Infliximab-induced palmoplantar psoriasis in a patient with ankylosing spondylitis. J Clin Rheumatol 2011;17:293-4.
Bal A, Gurcay E, Aydog E, Umay E, Tatlican S, Cakci A. Onset of psoriasis induced by infliximab. J Clin Rheumatol 2008;14:128-9.
Sarpel T, Basaran S, Akcam FD, Günasti S, Denli Y. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: Case series and literature overview. Turk J Rheumatol 2010;25:91-4.
Nalbant S, Özyurt M, Yıldırım M, Kuskucu M. Pulmonary tuberculosis and tuberculous arthritis of knee joint associated with rheumatoid arthritis treated with anti- tumor necrosis factor (TNF)-alpha medication: a case report. Rheumatol Int 2012;32:2863-6.
Bes C, Soy M. Serious menstrual bleeding associated with use of TNF alpha blocker: two cases. Rheumatol Int 2012;32:2175-6.
Akoğlu S, Babayiğit C, Karazincir S, Balci A, Hanta I. Tuberculous pleurisy after tumour necrosis factor-alpha antagonist usage: case report. [Article in Turkish] Tuberk Toraks 2008;56:448-52.
Akgul O, Calis M, Ozgocmen S. New-onset palmoplantar psoriasis during treatment of active ankylosing spondylitis with TNF-alpha blocking agent adalimumab. Turk J Rheumatol 2011;26:269-70.
Marakli SS, Uzun S, Ozbek S, Tuncer I. Dermatitis herpetiformis in a patient receiving infliximab for ankylosing spondylitis. Eur J Dermatol 2008;18:88-9.
Sari I, Binicier O, Birlik M, Akar S, Yilmaz E, Kargi A, et al. Thymic enlargement in a patient with juvenile idiopathic arthritis during etanercept therapy. Rheumatol Int 2009;29:591-3.
Ozgunes N, Zengin-Elbir T, Yazici S. Pulmonary tuberculosis following the use of infliximab: A case report. Klimik J 2010;23:70-2.
Elbek O, Uyar M, Aydin N, Börekçi S, Bayram N, Bayram H, et al. Increased risk of tuberculosis in patients treated with antitumor necrosis factor alpha. Clin Rheumatol 2009;28:421-6.
Korkmaz C, Kaşifoglu T, Yaşar B. Acceleration of left- ventricular diastolic dysfunction and pulmonary hypertension after TNF-alpha blocker. Ann Pharmacother 2005;39:1138-9.
Simsek I, Erdem H, Pay S, Sobaci G, Dinc A. Optic neuritis occurring with anti-tumour necrosis factor alpha therapy. Ann Rheum Dis 2007;66:1255-8.
Hanta I, Ozbek S, Kuleci S, Kocabas A. The evaluation of latent tuberculosis in rheumatologic diseases for anti-TNF therapy: experience with 192 patients. Clin Rheumatol 2008;27:1083-6.
Cagatay T, Aydin M, Sunmez S, Cagatay P, Gulbaran Z, Gul A, et al. Follow-up results of 702 patients receiving tumor necrosis factor-? antagonists and evaluation of risk of tuberculosis. Rheumatol Int 2010;30:1459-63.

APA	KILIÇ E, KILIÇ G, Akgul O, AKGÖL G, ÖZGÖÇMEN S (2013). The Reported Adverse Effects Related to Biological Agents Used for the Treatment of Rheumatic Diseases in Turkey. , 149 - 162.
Chicago	KILIÇ Erkan,KILIÇ GAMZE,Akgul Ozgur,AKGÖL Gürkan,ÖZGÖÇMEN Salih The Reported Adverse Effects Related to Biological Agents Used for the Treatment of Rheumatic Diseases in Turkey. (2013): 149 - 162.
MLA	KILIÇ Erkan,KILIÇ GAMZE,Akgul Ozgur,AKGÖL Gürkan,ÖZGÖÇMEN Salih The Reported Adverse Effects Related to Biological Agents Used for the Treatment of Rheumatic Diseases in Turkey. , 2013, ss.149 - 162.
AMA	KILIÇ E,KILIÇ G,Akgul O,AKGÖL G,ÖZGÖÇMEN S The Reported Adverse Effects Related to Biological Agents Used for the Treatment of Rheumatic Diseases in Turkey. . 2013; 149 - 162.
Vancouver	KILIÇ E,KILIÇ G,Akgul O,AKGÖL G,ÖZGÖÇMEN S The Reported Adverse Effects Related to Biological Agents Used for the Treatment of Rheumatic Diseases in Turkey. . 2013; 149 - 162.
IEEE	KILIÇ E,KILIÇ G,Akgul O,AKGÖL G,ÖZGÖÇMEN S "The Reported Adverse Effects Related to Biological Agents Used for the Treatment of Rheumatic Diseases in Turkey." , ss.149 - 162, 2013.
ISNAD	KILIÇ, Erkan vd. "The Reported Adverse Effects Related to Biological Agents Used for the Treatment of Rheumatic Diseases in Turkey". (2013), 149-162.

APA	KILIÇ E, KILIÇ G, Akgul O, AKGÖL G, ÖZGÖÇMEN S (2013). The Reported Adverse Effects Related to Biological Agents Used for the Treatment of Rheumatic Diseases in Turkey. Turkish Journal of Rheumatology(.)Archives of Rheumatology, 28(3), 149 - 162.
Chicago	KILIÇ Erkan,KILIÇ GAMZE,Akgul Ozgur,AKGÖL Gürkan,ÖZGÖÇMEN Salih The Reported Adverse Effects Related to Biological Agents Used for the Treatment of Rheumatic Diseases in Turkey. Turkish Journal of Rheumatology(.)Archives of Rheumatology 28, no.3 (2013): 149 - 162.
MLA	KILIÇ Erkan,KILIÇ GAMZE,Akgul Ozgur,AKGÖL Gürkan,ÖZGÖÇMEN Salih The Reported Adverse Effects Related to Biological Agents Used for the Treatment of Rheumatic Diseases in Turkey. Turkish Journal of Rheumatology(.)Archives of Rheumatology, vol.28, no.3, 2013, ss.149 - 162.
AMA	KILIÇ E,KILIÇ G,Akgul O,AKGÖL G,ÖZGÖÇMEN S The Reported Adverse Effects Related to Biological Agents Used for the Treatment of Rheumatic Diseases in Turkey. Turkish Journal of Rheumatology(.)Archives of Rheumatology. 2013; 28(3): 149 - 162.
Vancouver	KILIÇ E,KILIÇ G,Akgul O,AKGÖL G,ÖZGÖÇMEN S The Reported Adverse Effects Related to Biological Agents Used for the Treatment of Rheumatic Diseases in Turkey. Turkish Journal of Rheumatology(.)Archives of Rheumatology. 2013; 28(3): 149 - 162.
IEEE	KILIÇ E,KILIÇ G,Akgul O,AKGÖL G,ÖZGÖÇMEN S "The Reported Adverse Effects Related to Biological Agents Used for the Treatment of Rheumatic Diseases in Turkey." Turkish Journal of Rheumatology(.)Archives of Rheumatology, 28, ss.149 - 162, 2013.
ISNAD	KILIÇ, Erkan vd. "The Reported Adverse Effects Related to Biological Agents Used for the Treatment of Rheumatic Diseases in Turkey". Turkish Journal of Rheumatology(.)Archives of Rheumatology 28/3 (2013), 149-162.